Literature DB >> 17498057

Mast cell tryptases and chymases in inflammation and host defense.

George H Caughey1.   

Abstract

Tryptases and chymases are the major proteins stored and secreted by mast cells. The types, amounts, and properties of these serine peptidases vary by mast cell subtype, tissue, and mammal of origin. Membrane-anchored gamma-tryptases are tryptic, prostasin-like, type I peptidases that remain membrane attached on release and act locally. Soluble tryptases, including their close relatives, mastins, form inhibitor-resistant oligomers that act more remotely. Befitting their greater destructive potential, chymases are quickly inhibited after release, although some gain protection by associating with proteoglycans. Most chymase-like enzymes, including mast cell cathepsin G, hydrolyze chymotryptic substrates, an uncommon capability in the proteome. Some rodent chymases, however, have mutations resulting in elastolytic activity. Secreted tryptases and chymases promote inflammation, matrix destruction, and tissue remodeling by several mechanisms, including destroying procoagulant, matrix, growth, and differentiation factors and activating proteinase-activated receptors, urokinase, metalloproteinases, and angiotensin. They also modulate immune responses by hydrolyzing chemokines and cytokines. At least one chymase protects mice from intestinal worms. Tryptases and chymases can also oppose inflammation by inactivating allergens and neuropeptides causing inflammation and bronchoconstriction. Thus, like mast cells themselves, mast cell serine peptidases play multiple roles in host defense, and any accounting of benefit versus harm is necessarily context specific.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498057      PMCID: PMC2275918          DOI: 10.1111/j.1600-065X.2007.00509.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  138 in total

1.  Tryptase's potent mitogenic effects in human airway smooth muscle cells are via nonproteolytic actions.

Authors:  James K Brown; Cary A Jones; Leeann A Rooney; George H Caughey; Ian P Hall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-02       Impact factor: 5.464

2.  Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors.

Authors:  Norbert Schaschke; Andreas Dominik; Gabriele Matschiner; Christian P Sommerhoff
Journal:  Bioorg Med Chem Lett       Date:  2002-03-25       Impact factor: 2.823

3.  Hapten-specific tolerance induced by acute, low-dose ultraviolet B radiation of skin requires mast cell degranulation.

Authors:  P Alard; I Kurimoto; H Niizeki; J M Doherty; J W Streilein
Journal:  Eur J Immunol       Date:  2001-06       Impact factor: 5.532

4.  Mast cell alpha-chymase reduces IgE recognition of birch pollen profilin by cleaving antibody-binding epitopes.

Authors:  Matthew B Mellon; Brendon T Frank; Kenneth C Fang
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  Tryptase inhibition blocks airway inflammation in a mouse asthma model.

Authors:  Se-Woong Oh; Chong I Pae; Dong-Keun Lee; Falaah Jones; Gertrude K S Chiang; Hwa-Ok Kim; Sung-Hwan Moon; Bolong Cao; Cyprian Ogbu; Kwang-Won Jeong; Geoffrey Kozu; Hiroshi Nakanishi; Michael Kahn; Emil Y Chi; William R Henderson
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

6.  Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice.

Authors:  H Ju; R Gros; X You; S Tsang; M Husain; M Rabinovitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

7.  Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma.

Authors:  M T Krishna; A Chauhan; L Little; K Sampson; R Hawksworth; T Mant; R Djukanovic; T Lee; S Holgate
Journal:  J Allergy Clin Immunol       Date:  2001-06       Impact factor: 10.793

8.  Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors.

Authors:  M Jutel; T Watanabe; S Klunker; M Akdis; O A Thomet; J Malolepszy; T Zak-Nejmark; R Koga; T Kobayashi; K Blaser; C A Akdis
Journal:  Nature       Date:  2001-09-27       Impact factor: 49.962

9.  Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung.

Authors:  C Huang; G T De Sanctis; P J O'Brien; J P Mizgerd; D S Friend; J M Drazen; L F Brass; R L Stevens
Journal:  J Biol Chem       Date:  2001-05-02       Impact factor: 5.157

10.  Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study.

Authors:  W J Tremaine; A Brzezinski; J A Katz; D C Wolf; T J Fleming; J Mordenti; L C Strenkoski-Nix; M C Kurth
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

View more
  137 in total

1.  Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis.

Authors:  Lisa Scandiuzzi; Walid Beghdadi; Eric Daugas; Magnus Abrink; Neeraj Tiwari; Cristiana Brochetta; Julien Claver; Nassim Arouche; Xingxing Zang; Marina Pretolani; Renato C Monteiro; Gunnar Pejler; Ulrich Blank
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 2.  Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils.

Authors:  Stephen J Galli; Niels Borregaard; Thomas A Wynn
Journal:  Nat Immunol       Date:  2011-10-19       Impact factor: 25.606

Review 3.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

4.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 5.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 6.  Myeloid cells in atherosclerosis: initiators and decision shapers.

Authors:  Oliver Soehnlein; Christian Weber
Journal:  Semin Immunopathol       Date:  2009-02-24       Impact factor: 9.623

Review 7.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

Review 8.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

Review 9.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

10.  The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis.

Authors:  Adrian M Piliponsky; Ching-Cheng Chen; Eon J Rios; Piper M Treuting; Asha Lahiri; Magnus Abrink; Gunnar Pejler; Mindy Tsai; Stephen J Galli
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.